Abstract
Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 927-930 |
| Number of pages | 4 |
| Journal | Mayo Clinic Proceedings |
| Volume | 79 |
| Issue number | 7 |
| State | Published - 2004 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Linezolid-associated peripheral neuropathy. / Rho, Jennifer P.; Sia, Irene Gaw; Crum, Brian A.; Dekutoski, Mark B.; Trousdale, Robert T.
In: Mayo Clinic Proceedings, Vol. 79, No. 7, 2004, p. 927-930.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Linezolid-associated peripheral neuropathy
AU - Rho, Jennifer P.
AU - Sia, Irene Gaw
AU - Crum, Brian A.
AU - Dekutoski, Mark B.
AU - Trousdale, Robert T.
PY - 2004
Y1 - 2004
N2 - Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.
AB - Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.
UR - http://www.scopus.com/inward/record.url?scp=3042856503&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042856503&partnerID=8YFLogxK
M3 - Article
C2 - 15244392
AN - SCOPUS:3042856503
VL - 79
SP - 927
EP - 930
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 7
ER -